

Supplementary file. Reporting of suicidality in publications from the TADS study

Reporting parameter		Stage 1 (12 weeks)				Stage 2+3 (36 weeks)			Stage 4 (88 weeks)
		TADS team 2004 ⁶	Emslie ¹²	Kennard ¹³	May ¹⁴	TADS 2007 team ¹⁵	Kennard ¹⁶	Vitiello ¹⁷	TADS team 2009 ¹⁸
CDRS-R Item 13	% patients CDRS-R Item 13 score ≥2	Baseline: 27% 12 wk: 9.4%							
	% patients CDRS-R Item 13 score ≥6	Baseline: 2%							
	% patients CDRS-R Item 13 score ≥3		Baseline: 21.4%						
	% patients worsening CDRS-R Item 13 ≥1 point		COMB 5% FLX 13.4% CBT 15.2% PBO 7.2%						
	% patients increase CDRS Item 13 from 1-2 to ≥ 5		COMB 0 FLX 3.7% CBT 1.3% PBO 2.6%						
SIQ-Jr	% patients SIQ-Jr score ≥ 31	Baseline: 29% 12 wk: 10.3%	Baseline: 29.2%			Baseline: 97/320 (30.3%) COMB 42/106 (39.6%) Stage 1 (12 wk) Completed score All: 31/278 (11.2%) COMB 8/90 (8.9%) FLX 18/97 (18.6%) CBT 5/91 (5.5%) Observed cases All: 24/257 (9.3%) COMB 5/84 (6.0%) FLX 14/89 (15.7%) CBT 5/84 (6.0%) Stage 3 (36 wk) All: 15/228 (6.6%) COMB 2/79 (2.5%) FLX 10/73 (13.7%) CBT 3/76 (3.9%)			Baseline: COMB 1/78 (1.3%) FLX 4/73 (5.5%) CBT 0/76 (0%)
	% patients SIQ-Jr score increase to ≥ 31		All: 4.8% (18/374) COMB 2.2% (2/93) FLX 7.3% (7/96) CBT 2.2% (2/93) PBO 7.6% (7/92)					All: 6.4% COMB 5.9% FLX 7.6% CBT 6.4%	
	SIQ-Jr score adjusted mean ±SD	Baseline: COMB 27.33 (18.51) FLX 21.81 (15.68) CBT 21.91 (16.28) PBO 24.20 (16.46) 12 wk: COMB 11.79 (11.69) FLX 14.44 (11.13) CBT 11.40 (10.44) PBO 15.01 (11.05)	12 wk: COMB 10.9 ± 0.3 FLX 13.7 ± 0.2 CBT 11.3 ± 0.3 PBO 14.5 ± 0.6					36 wk: COMB 10.2 ± 8.8 FLX 12.1 ± 11.1 CBT 9.5 ± 9.1 88 wk: COMB 9.3 ± 7.8 FLX 10.5 ± 10.4 CBT 8.2 ± 8.1	

Supplementary file. Reporting of suicidality in publications from the TADS study, cont'd.

Reporting parameter	Stage 1 (12 weeks)				Stage 2+3 (36 weeks)			Stage 4 (88 weeks)	
	TADS team 2004 ⁶	Emslie ¹²	Kennard ¹³	May ¹⁴	TADS team 2007 ¹⁵		Kennard ¹⁶	Vitiello ¹⁷	TADS team 2009 ¹⁸
Number of cases	Harm-related AE†	All: 33/439 (7.5%) Serious: 23/33 (69.7%) COMB 9/107 (8.41%) FLX 13/109 (11.93%) CBT 5/111 (4.50%) PBO 6/112 (5.36%)							
	Suicide-related AE†	All: 24/439 (5.5%) COMB 6/107 (5.61%) FLX 9/109 (8.26%) CBT 5/111 (4.50%) PBO 4/112 (3.57%)	24 (5.5%) COMB 5 (4.7) FLX 10 (9.2%) CBT 5 (4.5%) PBO 3 (2.7%)		16/78				
	Suicidal event†					Stage 1 (12 wk) Observed cases Intention-to-treat All: 20/327 (6.1%) All: 22/327 (6.7%) COMB 5/107 (4.7%) COMB 5/107 (4.7%) FLX 10/109 (9.2%) FLX 12/109 (11.0%) CBT 5/111 (4.5%) CBT 5/111 (4.5%) Stage 3 (36 weeks) All: 26/327 (8.0%) All: 32/327 (9.8%) COMB 8/107 (7.5%) COMB 9/107 (8.4%) FLX 12/109 (11.0%) FLX 16/109 (14.7%) CBT 6/111 (5.4%) CBT 7/111 (6.3%)	Stage 2-3 (12-36 wk) PBO/Open 10.7% (12/112) Active 32/327 (9.8%)	All: 44/439 (10.0%) SSRI at event: 36 COMB 9/107 (8.4%) FLX 16/109 (14.7%) CBT 7/111 (6.3%) (5 CBT, 2 SSRI at event) PBO 12/112 (10.7%) (3 PBO, 9 SSRI at event)	
	Suicidal. inc. self-harm				27/78 (37.6%)				
	Thoughts self-harm				8/27 (29.6%)				
	Plan self-harm				8/27 (29.6%)				
	Intent self-harm				4/27 (14.8%)				
	Attempt self-harm				All: 7/27 (25.9%) COMB 1 FLX 4 CBT 1 PBO 1				
	Intend, plan, attempt self-harm				All: 16 COMB 3 FLX 7 CBT 3 PBO 4				
	Intend, plan, attempt suicide (Columbia reassess.)				All: 9 COMB 2 FLX 3 CBT 2 PBO 2				

Supplementary file. Reporting of suicidality in publications from the TADS study, cont'd.

Reporting parameter		Stage 1 (12 weeks)				Stage 2+3 (36 weeks)			Stage 4 (88 weeks)
		TADS team 2004 ⁶	Emslie ¹²	Kennard ¹³	May ¹⁴	TADS team 2007 ¹⁵	Kennard ¹⁶	Vitiello ¹⁷	TADS team 2009 ¹⁸
Number of cases	Suicidal ideation†		All: 18 (4.1%) COMB 3 (2.8%) FLX 8 (7.3%) CBT 4 (3.6%) PBO 3 (2.7%)	6/129 (remitters, from fig.)				All: 23/439 (5.2%) COMB 5/107 (4.7%) FLX 9/109 (8.3%) CBT 3/111 (2.7%) PBO 6/112 (5.4%)	
	Suicide-related AE, Columbia 1,2,6 †		All: 23 (5.2%) COMB 5 (4.7%) FLX 10 (9.2%) CBT 5 (4.5%) PBO 3 (2.7%)					All: 44/439 (10.0%) COMB 9/107 (8.4%) FLX 16/109 (14.7%) CBT 7/111 (6.3%) PBO 12/112 (10.7%)	
	Suicide-related AE, Columbia 1,2,3,6 †		All: 24 (5.5%) Serious: 15 COMB 6 (5.6%) FLX 10 (9.2%) CBT 5 (4.5%) PBO 3 (2.7%)						
	Attempt suicide†	All: 7/439 (1.6%) COMB 4 FLX 2 CBT 1	All: 5 COMB 2 FLX 2 CBT 1 PBO 0					All: 21/439 (4.8%) COMB 4/107 (3.7%) FLX 7/109 (6.4%) CBT 4/111 (3.6%) PBO 6/112 (5.4%)	

† Frequency calculations based on ITT groups